Eli Lilly and Company $LLY Shares Purchased by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky raised its holdings in Eli Lilly and Company (NYSE:LLY) by 3.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 165,165 shares of the company’s stock after acquiring an additional 5,595 shares during the quarter. Eli Lilly and Company accounts for about 1.0% of Teachers Retirement System of The State of Kentucky’s portfolio, making the stock its 11th biggest holding. Teachers Retirement System of The State of Kentucky’s holdings in Eli Lilly and Company were worth $126,022,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the business. Brighton Jones LLC raised its position in shares of Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares during the period. Revolve Wealth Partners LLC lifted its stake in Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after buying an additional 40 shares in the last quarter. OneAscent Wealth Management LLC boosted its holdings in shares of Eli Lilly and Company by 32.0% in the second quarter. OneAscent Wealth Management LLC now owns 359 shares of the company’s stock worth $280,000 after buying an additional 87 shares during the period. Sequoia Financial Advisors LLC increased its position in shares of Eli Lilly and Company by 19.0% in the second quarter. Sequoia Financial Advisors LLC now owns 140,201 shares of the company’s stock worth $109,291,000 after acquiring an additional 22,410 shares in the last quarter. Finally, Schnieders Capital Management LLC. raised its holdings in shares of Eli Lilly and Company by 16.7% during the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after acquiring an additional 1,141 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Orforglipron launch on deck — CFO said Lilly is preparing to launch its oral obesity drug in the U.S. as early as Q2 pending FDA approval, which would be a major new revenue stream if cleared. Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval
• Positive Sentiment: Regulatory win in EU — CHMP backed expanded use of Olumiant for adolescents with severe alopecia areata, increasing near‑term sales opportunities in immunology while an EU decision is expected soon. LLY Wins CHMP Nod for Olumiant’s Expanded Use in Alopecia Areata
• Positive Sentiment: Institutional buying noted — filings and commentary suggest smart‑money accumulation during a recent pullback, which can support the stock if momentum re‑accelerates. What Smart Money Loves About Lilly
• Neutral Sentiment: Industry backdrop — Zacks and other analysts flag large‑cap pharma recovery and keep Lilly on watch as part of sector rebound, a contextual tailwind but not an immediate catalyst. Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Sanofi and Bayer
• Neutral Sentiment: Investor meetings and presentations — Lilly’s TD Cowen conference presentation (transcript) provides management color on pipeline and commercialization plans; useful for modeling but not a headline surprise. Eli Lilly and Company (LLY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
• Neutral Sentiment: Analyst consensus remains constructive — coverage shows an average “Moderate Buy,” offering support but also reflecting already elevated expectations. Eli Lilly and Company (NYSE:LLY) Receives Average Recommendation of “Moderate Buy” from Analysts
• Negative Sentiment: Valuation and momentum cooling — multiple writeups note recent short‑term negative returns and that shares trade at elevated multiples after a multi‑year run, increasing sensitivity to any misses or slower growth. Eli Lilly (LLY) Valuation Check As Momentum Cools After Strong Multi Year Run
• Negative Sentiment: Competition and capacity — Novo Nordisk’s sizable Ireland capacity expansion is a strategic move to defend share in obesity/oral drug markets, posing competitive pressure on Lilly’s launch and pricing dynamics. Why Novo Nordisk’s Ireland expansion is key to fighting off Eli Lilly

Eli Lilly and Company Price Performance

Shares of LLY opened at $1,017.97 on Tuesday. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. The firm has a market cap of $960.31 billion, a PE ratio of 44.36, a PEG ratio of 1.22 and a beta of 0.40. The firm’s 50 day moving average price is $1,051.98 and its 200 day moving average price is $934.28. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The business had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. During the same quarter last year, the firm earned $5.32 EPS. Eli Lilly and Company’s revenue for the quarter was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a $1.73 dividend. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s payout ratio is presently 30.15%.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of recent analyst reports. Wells Fargo & Company raised their price objective on shares of Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Wolfe Research upped their price target on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a research report on Wednesday, December 3rd. Guggenheim increased their price objective on Eli Lilly and Company from $1,161.00 to $1,168.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Truist Financial reissued a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 23rd. Finally, Zacks Research downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,229.59.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.